Amplia Therapeutics Management
Management criteria checks 1/4
Amplia Therapeutics' CEO is Chris Burns, appointed in Dec 2022, has a tenure of 1.33 years. total yearly compensation is A$1.53M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth A$151.67K. The average tenure of the management team and the board of directors is 1.3 years and 5 years respectively.
Key information
Chris Burns
Chief executive officer
AU$1.5m
Total compensation
| CEO salary percentage | 7.0% |
| CEO tenure | 1.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -AU$4m |
| Jun 30 2023 | n/a | n/a | -AU$5m |
| Mar 31 2023 | AU$2m | AU$106k | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$6m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | n/a | n/a | -AU$4m |
| Mar 31 2022 | AU$22k | n/a | -AU$4m |
| Dec 31 2021 | n/a | n/a | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$3m |
| Jun 30 2021 | n/a | n/a | -AU$3m |
| Mar 31 2021 | AU$20k | n/a | -AU$2m |
| Dec 31 2020 | n/a | n/a | -AU$2m |
| Sep 30 2020 | n/a | n/a | -AU$2m |
| Jun 30 2020 | n/a | n/a | -AU$2m |
| Mar 31 2020 | AU$20k | n/a | -AU$2m |
Compensation vs Market: Chris's total compensation ($USD994.56K) is above average for companies of similar size in the Australian market ($USD290.69K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Burns (58 yo)
1.3yrs
Tenure
AU$1,525,859
Compensation
Dr. Christopher J. Burns, also known as Chris, B.Sc. (Hons), Ph.D. FRACI FRSC, GAICD, serves as the CEO of MetabloQ Pty Ltd. Dr. Burns served as an Independent Non-Executive Director of Amplia Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.3yrs | AU$1.53m | 1.3% A$ 151.7k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Company Secretary | 10.5yrs | AU$113.95k | no data |
1.3yrs
Average Tenure
Experienced Management: ATX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 5.9yrs | AU$1.53m | 1.3% A$ 151.7k | |
| Independent Non-Executive Chairman | 5.9yrs | AU$97.37k | 1.55% A$ 181.0k | |
| Independent Non-Executive Director | 8.6yrs | AU$69.52k | 0.86% A$ 99.9k | |
| Independent Non-Executive Director | 3yrs | AU$69.52k | 1.04% A$ 121.5k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | 1.14% A$ 132.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data |
5.0yrs
Average Tenure
67yo
Average Age
Experienced Board: ATX's board of directors are considered experienced (5 years average tenure).